Advertisement

Canadian Journal of Public Health

, Volume 98, Issue 5, pp 412–416 | Cite as

Statin Use in Canadians: Trends, Determinants and Persistence

  • C. Ineke NeutelEmail author
  • Howard Morrison
  • Norm R. C. Campbell
  • Margaret de Groh
Article
  • 1 Downloads

Abstract

Background

Regular statin use is an important tool in chronic disease management, lowering cholesterol levels and reducing risk of cardiovascular disease (CVD). The objectives of this study are to describe statin use in Canada by comorbidity and lifestyle risk factors, and determine persistence in statin use.

Methods

The longitudinal National Population Health Survey, 1994–2002, is a random sample of the 1994 Canadian population and five interviews were conducted at two-year intervals. A total of 8,198 respondents, aged 20 in 1994, completed all five interviews. Information collected included demographic variables, medication use, CVD lifestyle risk factors, CVD, diabetes and hypertension.

Results

Age-adjusted rates of statin use increased from 1.6% to 7.8% over the period 1994–2002. Statin use was higher with increasing age, diabetes, BMI, physician visits, and insurance for prescription medication. Although persons with CVD were more likely to take statins than those without, by 2002 still only 32.7% of heart patients were taking statins. Statin use did not increase linearly with increasing numbers of CVD risk factors or comorbidities. Of the 441 persons reporting statin use in 2000, 74.6% were still taking them in 2002. People who completed their high school education were more likely to continue taking statins than those who did not complete high school.

Conclusion

While statin use increased over time, was associated with CVD and diabetes, and to a lesser extent with increased BMI, a substantive underuse in high-risk patients remains. Helping high-risk people to increase statin use continues to be a priority for health care professionals.

MeSH terms

Statins comorbidity risk factors trends epidemiologic determinants Persistence 

Résumé

Contexte

La prise régulière de statine est un outil important dans le traitement des maladies chroniques et la réduction de la cholestérolémie et des risques de maladie cardiovasculaire (MCV). Nous avons voulu décrire l’utilisation des statines au Canada en fonction de deux facteurs (la comorbidité et le risque lié aux habitudes de vie) et déterminer la persistance dans la prise de statine.

Méthode

Cinq entretiens ont été menés tous les deux ans dans le cadre de l’Enquête nationale sur la santé de la population (1994–2002), une enquête longitudinale auprès d’un échantillon aléatoire de la population canadienne. En tout, 8 198 répondants âgés de 20 ans en 1994 se sont prêtés aux cinq entretiens. Les données recueillies englobaient des variables démographiques, la consommation de médicaments, les facteurs de risque de MCV liés aux habitudes de vie, les MCV, le diabète et l’hypertension artérielle.

Résultats

Les taux de prise de statine rajustés selon l’âge ont grimpé de 1,6 % à 7,8 % entre 1994 et 2002. La prise de statine s’élevait avec l’âge, le diabète, l’indice de masse corporelle (IMC), les visites chez le médecin et le fait d’avoir une assurance-médicaments. Les personnes ayant une MCV étaient plus susceptibles de prendre des statines que les personnes qui n’en avaient pas, mais en 2002, les cardiaques qui prenaient des statines n’étaient encore que 32,7 %. La prise de statine n’a pas augmenté de façon linéaire avec les facteurs de risque de MCV ou les comorbidités. Sur les 441 personnes qui prenaient des statines en 2000, 74,6 % en prenaient encore en 2002. Les diplômés du secondaire étaient plus susceptibles d’avoir continué à prendre des statines que les non-diplômés.

Conclusion

La prise de statine a augmenté au fil du temps, et elle était associée à l’augmentation des MCV, du diabète et, dans une moindre mesure, de l’IMC, mais les patients à risque élevé sousutilisaient encore beaucoup ce médicament. Aider les personnes à risque élevé à accroître leur prise de statine demeure donc une priorité pour les professionnels de la santé.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Naslafkih A, Sestier F. Expected versus observed survival in 3 large population studies with HMGCoA reductase inhibitors. J Insur Med 2000;32(3):155–62.PubMedGoogle Scholar
  2. 2.
    Jacobson, TA. “The lower the better” in hypercholesterolemia therapy: A reliable clinical guideline? Ann Intern Med 2000;133(7):549–54.CrossRefGoogle Scholar
  3. 3.
    Gotto AM Jr. Risk factor modification: Rationale for management of dyslipidemia. Am J Med 1998;104(2A):6S–8S.CrossRefGoogle Scholar
  4. 4.
    Gotto AM Jr. Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin. Am J Cardiol 2005;96(5A):34F–8F.CrossRefGoogle Scholar
  5. 5.
    Ray JG, Gong Y, Sykora K, Tu, JV. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 2005;165(1):62–67.CrossRefGoogle Scholar
  6. 6.
    Genest J, Frohlich J, Fodor G, McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: Summary of the 2003 update. CMAJ 2003;169(9):921–24.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Fodor JG, Frohlich JJ, Genest JJ Jr, McPherson PR. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. CMAJ 2000;162(10): 1441–47.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: Economic analysis of a randomized trial in 20,536 individuals. Lancet 2005;365(9473):1779–85.CrossRefGoogle Scholar
  9. 9.
    Wellman NS, Friedberg B. Causes and consequences of adult obesity: Health, social and economic impacts in the United States. Asia Pac J Clin Nutr 2002;11(Suppl. 8):S705–S709.CrossRefGoogle Scholar
  10. 10.
    Siegel D, Lopez J, Meier J. Use of cholesterollowering medications in the United States from 1991 to 1997. Am J Med 2000;108:496–99.CrossRefGoogle Scholar
  11. 11.
    Tonstad S, Rosvold EO, Furu K, Skurtveit S. Undertreatment and overtreatment with statins: The Oslo Health Study 2000–2001. J Intern Med 2004;255(4):494–502.CrossRefGoogle Scholar
  12. 12.
    Walop W, Semenchuk M. Coding of drugs used by respondents of the Canadian study of health and aging. Can J Clin Pharmacol 2002;9:64–68.PubMedGoogle Scholar
  13. 13.
    WHO Collaborating Centre for Drug Statistics Methodology/Nordic Council on Medicines. Guidelines for ATC classification. Oslo, 1990.Google Scholar
  14. 14.
    Jackevicius CA, Tu K, Filate WA, Brien SE, Tu JV. Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996–2001. Can J Cardiol 2003;19:1359–66.PubMedGoogle Scholar
  15. 15.
    Carroll MD, Lacher DA, Sorlie PD, Cleeman JI, Gordon DJ, Wolz M, et al. Trends in serum lipids and lipoproteins of adults, 1960–2002. JAMA 2005;294(14):1773–81.CrossRefGoogle Scholar
  16. 16.
    Manuel DG, Tanuseputro P, Mustard CA, Schultz SE, Anderson GM, Ardal S, et al. The 2003 Canadian recommendations for dyslipidemia management: Revisions are needed. CMAJ 2005;172(8):1027–31.CrossRefGoogle Scholar
  17. 17.
    Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. The CARE Investigators. Circulation 1998;98(23):2513–19.CrossRefGoogle Scholar
  18. 18.
    Yang CC, Jick SS, Testa, MA. Who receives lipidlowering drugs: The effects of comorbidities and patient characteristics on treatment initiation. Br J Clin Pharmacol 2003;55(3):288–98.CrossRefGoogle Scholar
  19. 19.
    Savoie I, Kazanjian A. Utilization of lipid-lowering drugs in men and women: A reflection of the research evidence. J Clin Epidemiol 2002;55:95–101.CrossRefGoogle Scholar
  20. 20.
    Bourgault C, Davignon J, Fodor G, Gagne C, Gaudet D, Genest J, et al. Statin therapy in Canadian patients with hypercholesterolemia: The Canadian Lipid Study — Observational (CALIPSO). Can J Cardiol 2005;21:1187–93.PubMedGoogle Scholar
  21. 21.
    Jackevicius CA, Alter D, Cox J, Daly P, Goodman S, Filate W, et al. Acute treatment of myocardial infarction in Canada 1999–2002. Can J Cardiol 2005;21:142–52.Google Scholar
  22. 22.
    Pilote L, Beck CA, Karp I, Alter D, Austin P, Cox J, et al. Secondary prevention after acute myocardial infarction in four Canadian provinces, 1997–2000. Can J Cardiol 2004;20:61–67.PubMedGoogle Scholar
  23. 23.
    Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet 2005;365(9457):434–41.CrossRefGoogle Scholar
  24. 24.
    Baker S, Priest P, Jackson R. Using thresholds based on risk of cardiovascular disease to target treatment for hypertension: Modeling events averted and number treated. BMJ 2000;320(7236):680–85.CrossRefGoogle Scholar
  25. 25.
    Grover SA, Dorais M, Paradis G, Fodor JG, Frohlich JJ, McPherson R, et al. Lipid screening to prevent coronary artery disease: A quantitative evaluation of evolving guidelines. CMAJ 2000;163(10):1263–69.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Grover SA, Coupal L, Zowall H, Alexander CM, Weiss TW, Gomes, DR. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 2001;24(1):45–50.CrossRefGoogle Scholar
  27. 27.
    Grover SA, Coupal L, Zowall H, Dorais M. Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: Who should be treated? Circulation 2000;102(7):722–27.CrossRefGoogle Scholar
  28. 28.
    Perreault S, Dorais M, Coupal L, Paradis G, Joffres MR, Grover, SA. Impact of treating hyperlipidemia or hypertension to reduce the risk of death from coronary artery disease. CMAJ 1999;160(10):1449–55.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Perreault S, Blais L, Dragomir A, Bouchard MH, Lalonde L, Laurier C, Collin J. Persistence and determinants of statin therapy among middleaged patients free of cardiovascular disease. Eur J Clin Pharmacol 2005;61:667–74.CrossRefGoogle Scholar
  30. 30.
    Grant RW, O’Leary KM, Weilburg JB, Singer DE, Meigs, JB. Impact of concurrent medication use on statin adherence and refill persistence. Arch Intern Med 2004;164(21):2343–48.CrossRefGoogle Scholar
  31. 31.
    Abughosh SM, Kogut SJ, Andrade SE, Larrat P, Gurwitz, JH. Persistence with lipid-lowering therapy: Influence of the type of lipid-lowering agent and drug benefit plan option in elderly patients. J Manag Care Pharm 2004;10(5):404–11.PubMedGoogle Scholar
  32. 32.
    Benner JS, Pollack MF, Smith TW, Bullano MF, Willey VJ, Williams, SA. Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. Am J Health Syst Pharm 2005;62(14):1468–75.CrossRefGoogle Scholar
  33. 33.
    Perreault S, Blais L, Lamarre D, Dragomir A, Berbiche D, Lalonde L, et al. Persistence and determinants of statin therapy among middleaged patients for primary and secondary prevention. Br J Clin Pharmacol 2005;59(5):564–73.CrossRefGoogle Scholar
  34. 34.
    Tolmie EP, Lindsay GM, Kerr SM, Brown MR, Ford I, Gaw A. Patients’ perspectives on statin therapy for treatment of hypercholesterolaemia: A qualitative study. Eur J Cardiovasc Nurs 2003;2(2):141–49.CrossRefGoogle Scholar
  35. 35.
    Metge C, Kozyrskyj A, Dahl M, Yogendran M, Roos N. Pharmaceuticals: Focusing on Appropriate Utilization. Manitoba Health: Manitoba Centre for Health Policy, 2003.Google Scholar
  36. 36.
    Flaker GC, Warnica JW, Sacks FM, Moye LA, Davis BR, Rouleau JL, et al. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. J Am Coll Cardiol 1999;34(1):106–12.CrossRefGoogle Scholar
  37. 37.
    MacLean DR, Petrasovits A, Connelly PW, Little JA, O’Connor B. Impact of different blood lipid evaluation and treatment guidelines on the proportion of Canadians identified and treated for elevated blood cholesterol. Canadian Heart Health Surveys Research Group. Can J Cardiol 1999;15(4):445–51.PubMedGoogle Scholar
  38. 38.
    Tran CTT, Lee DS, Flintoff VF, Higginson L, Grant C, Tu, JV. CCORT/CCS quality indicators for acute myocardial infarction care. Can J Cardiol 2003;19:38–45.PubMedGoogle Scholar
  39. 39.
    Joffres MR, Kamath TV, Williams GR, Casey J, Svenson, LW. Impact of guidelines on health care use for the management of dyslipidemia in two Canadian provinces, Alberta and Nova Scotia, from 1990 to 2001. Can J Cardiol 2004;20(8):767–72.PubMedGoogle Scholar
  40. 40.
    Joffres MR, Ghadirian P, Fodor JG, Petrasovits A, Chockalingam A, Hamet P. Awareness, treatment, and control of hypertension in Canada. Am J Hypertens 1997;10:1097–102.CrossRefGoogle Scholar
  41. 41.
    Ma J, Sehgal NL, Ayanian JZ, Stafford, RS. National trends in statin use by coronary heart disease risk category. PLoS Med 2005;2(5):e123.Google Scholar

Copyright information

© The Canadian Public Health Association 2007

Authors and Affiliations

  • C. Ineke Neutel
    • 1
    • 2
    Email author
  • Howard Morrison
    • 1
    • 2
  • Norm R. C. Campbell
    • 3
  • Margaret de Groh
    • 1
  1. 1.Centre for Chronic Diseases Prevention and ControlPublic Health Agency of CanadaOttawaCanada
  2. 2.Department of Epidemiology and Community Medicine, Faculty of MedicineUniversity of OttawaCanada
  3. 3.Departments of Medicine, and Pharmacology & Therapeutics, Faculty of MedicineUniversity of CalgaryCalgaryCanada

Personalised recommendations